Prima BioMed (IMMP) Stock Price, News & Analysis

Company Overview

Prima BioMed is a clinical‐stage biotechnology company specializing in the development of immuno‐oncology therapies. Founded in 2001 and headquartered in Sydney, Australia, the company applies its proprietary LAG-3 platform to modulate the immune response against cancer. This approach leverages both agonist and antagonist strategies to enhance antigen presentation and stimulate T-cell activity, aiming to overcome the limitations of existing checkpoint inhibitors.

The company’s lead asset, eftilagimod alpha (IMP321), is a first‐in‐class soluble LAG-3 fusion protein designed to activate antigen‐presenting cells. Eftilagimod alpha is currently being evaluated in combination with pembrolizumab in Phase II trials for patients with metastatic breast cancer, building on earlier studies in melanoma and non‐small cell lung cancer. Prima BioMed’s pipeline also includes next‐generation LAG-3 antagonists that are in preclinical and early clinical development for solid tumors.

Prima BioMed has pursued a global clinical development strategy, conducting trials across key oncology centers in North America, Europe and Australia. The company maintains research partnerships with leading academic institutions and collaborates with clinical investigators to advance its immunotherapy candidates. Prima BioMed’s intellectual property portfolio includes multiple patents covering LAG-3 mechanisms, therapeutic compositions and manufacturing processes.

The company’s leadership team combines biotech industry veterans with deep expertise in oncology drug development and regulatory affairs. Executive Chairman Paul Hopper co‐founded Prima BioMed and brings extensive experience in life‐science funding and strategy, while Chief Executive Officer Marc Voigt oversees clinical operations and corporate development. Together, they guide Prima BioMed’s efforts to bring novel immunotherapies to patients with unmet medical needs.

Key Stats

• Today's Range: $1.66 to $1.74
• 50-Day Range: $1.52 to $2.49
• 52-Week Range: $1.32 to $2.72
• Volume: 64,776 shs
• Average Volume: 191,365 shs
• Market Capitalization: $246.81 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Buy

Prima BioMed Stock Analysis - MarketRank™

Prima BioMed scored higher than 19% of companies evaluated by MarketBeat, and ranked 845th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Prima BioMed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Prima BioMed has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Prima BioMed are expected to decrease in the coming year, from ($0.40) to ($0.50) per share.

Price to Book Value per Share Ratio

Prima BioMed has a P/B Ratio of 1.61. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.96% of the float of Prima BioMed has been sold short.

Short Interest Ratio / Days to Cover

Prima BioMed has a short interest ratio ("days to cover") of 14.8, which indicates bearish sentiment.

Change versus previous month

Short interest in Prima BioMed has recently increased by 1.21%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Prima BioMed does not currently pay a dividend.

Dividend Growth

Prima BioMed does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.96% of the float of Prima BioMed has been sold short.

Short Interest Ratio / Days to Cover

Prima BioMed has a short interest ratio ("days to cover") of 14.8, which indicates bearish sentiment.

Change versus previous month

Short interest in Prima BioMed has recently increased by 1.21%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

3 people have searched for IMMP on MarketBeat in the last 30 days.

MarketBeat Follows

Only 1 people have added Prima BioMed to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Prima BioMed insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.07% of the stock of Prima BioMed is held by insiders.

Percentage Held by Institutions

Only 2.32% of the stock of Prima BioMed is held by institutions.

IMMP Stock Analysis - Frequently Asked Questions

How have IMMP shares performed this year?

Prima BioMed's stock was trading at $2.17 at the start of the year. Since then, IMMP shares have decreased by 22.1% and is now trading at $1.69.

How do I buy shares of Prima BioMed?

Shares of IMMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Prima BioMed own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Prima BioMed investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), Pfizer (PFE), Broadcom (AVGO) and GE Aerospace (GE).

Company Calendar

• Today: 7/09/2025
• Next Earnings (Estimated): 7/29/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IMMP
• CIK: 1506184
• Web: www.immutep.com
• Phone: (128) 315-7003
• Fax: 61-2-8569-1880
• Employees: 2,021
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Prima BioMed: $7.00
• High Price Target: $7.00
• Low Price Target: $7.00
• Potential Upside/Downside: +305.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 18.86
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $5.14 million
• Price / Sales: 49.04
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.05 per share
• Price / Book: 1.64

Miscellaneous

• Outstanding Shares: 146,040,000
• Free Float: 141,556,000
• Market Cap: $252.07 million
• Optionable: Optionable
• Beta: 1.71